Quarterly report pursuant to Section 13 or 15(d)

CONCENTRATIONS

v3.4.0.3
CONCENTRATIONS
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note 15 - CONCENTRATIONS

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. 

 

The Company's revenues earned from sale of products and services for the three months ended March 31, 2016 included 12%, 15% and 16% (aggregate of 43%) from three customers of the Company's total revenues. 

 

The Company's revenues earned from sale of products and services for the three months ended March 31, 2015 included 38%, 15% and 18% (aggregate of 71%) from three customers of the Company's total revenues.

 

Four customers accounted for 12%, 36%, 15% and 11% (aggregate of 74%) of the Company's total accounts receivable at March 31, 2016 and two customers accounted for 49% and 20% of the Company's total accounts receivable at December 31, 2015. 

 

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.